Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Study recommends treatment change for pre-leukemia disease

14.03.2006


A new study finds that longer courses of a mild form of chemotherapy may help patients with a bone marrow disease only recently considered a form of cancer. Writing in the April 15, 2006 issue of CANCER, a peer-reviewed journal of the American Cancer Society, researchers say the study found that 45 percent of patients with Myelodysplastic Syndrome (MDS) who relapse did respond to a second course of treatment, but that the quality and duration of the second response was inferior to the initial treatment, leading researchers to believe that longer initial treatments may be more beneficial to patient outcome.



MDS is a bone marrow disease that causes an increasing number of dysfunctional blood cells called blasts to develop from stem cells and proliferate in the blood stream at the expense of normal cells. As a result, fewer normal red blood cells will circulate to carry oxygen to cells resulting in anemia; fewer white blood cells will be available to fight infections; and fewer platelets to control bleeding. Although MDS has not been considered cancer in the past, most hematologists (specialists in diseases of the blood) now think it is a form of bone marrow cancer (i.e. leukemia).

MDS generally afflicts adults over 50 years old, and therapy is supportive rather than curative. However, a subset of MDS patients will develop blood cell cancer, or leukemia. These high-risk patients have been shown to benefit from a new DNA hypomethylating agent, decitabine, undergoing clinical trials. The results of these trials are revealed in a related article by Kantarjian et al. also published in the April 15, 2006 issue of CANCER.


Little is known about the optimal duration of treatment with decitabine and the effect of retreatment for relapse. Led by Michael Lübbert, M.D., Ph.D. of the University of Freiburg Medical Center in Freiburg, Germany, researchers assessed the efficacy of decitabine retreatment on relapsing high-risk MDS patients who received initial treatment with decitabine.

The researchers found that retreatment with a median of three courses of decitabine resulted in 10 patients out of 22 (45 percent) achieving any response. Three of the patients achieved a partial or complete response in all three cell lines, while the other seven patients experienced hematologic improvements of an at least 50 percent drop in transfusion requirements and higher counts in one or two blood cell lines. The median overall survival of all patients from the start of the first decitabine course was 28 months. Decitabine-retreated patients had a median survival of 13 months from relapse

Decitabine retreatment in the 12 patients (55 percent) not achieving a second response either suppressed the abnormal cells without bone marrow repopulation with normal cells, resulting in cytopenia (blood cell deficiency), or had no effect on normal or abnormal cell lines. Of these 12 retreatment failures, four patients developed acute leukemia and three patients died of complications due to pathological deficiencies in cell lines.

The authors conclude, "results of the present analysis point to the importance of extending therapy with low-dose decitabine beyond the point of first response, and strongly support institution of a maintenance treatment." This type of continued outpatient maintenance treatment is presently studied by the authors in a multicenter clinical trial in older patients with acute myeloid leukemia.

David Greenberg | EurekAlert!
Further information:
http://www.wiley.com
http://www.interscience.wiley.com/cancer-newsroom

More articles from Studies and Analyses:

nachricht Win-win strategies for climate and food security
02.10.2017 | International Institute for Applied Systems Analysis (IIASA)

nachricht The personality factor: How to foster the sharing of research data
06.09.2017 | ZBW – Leibniz-Informationszentrum Wirtschaft

All articles from Studies and Analyses >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Neutron star merger directly observed for the first time

University of Maryland researchers contribute to historic detection of gravitational waves and light created by event

On August 17, 2017, at 12:41:04 UTC, scientists made the first direct observation of a merger between two neutron stars--the dense, collapsed cores that remain...

Im Focus: Breaking: the first light from two neutron stars merging

Seven new papers describe the first-ever detection of light from a gravitational wave source. The event, caused by two neutron stars colliding and merging together, was dubbed GW170817 because it sent ripples through space-time that reached Earth on 2017 August 17. Around the world, hundreds of excited astronomers mobilized quickly and were able to observe the event using numerous telescopes, providing a wealth of new data.

Previous detections of gravitational waves have all involved the merger of two black holes, a feat that won the 2017 Nobel Prize in Physics earlier this month....

Im Focus: Smart sensors for efficient processes

Material defects in end products can quickly result in failures in many areas of industry, and have a massive impact on the safe use of their products. This is why, in the field of quality assurance, intelligent, nondestructive sensor systems play a key role. They allow testing components and parts in a rapid and cost-efficient manner without destroying the actual product or changing its surface. Experts from the Fraunhofer IZFP in Saarbrücken will be presenting two exhibits at the Blechexpo in Stuttgart from 7–10 November 2017 that allow fast, reliable, and automated characterization of materials and detection of defects (Hall 5, Booth 5306).

When quality testing uses time-consuming destructive test methods, it can result in enormous costs due to damaging or destroying the products. And given that...

Im Focus: Cold molecules on collision course

Using a new cooling technique MPQ scientists succeed at observing collisions in a dense beam of cold and slow dipolar molecules.

How do chemical reactions proceed at extremely low temperatures? The answer requires the investigation of molecular samples that are cold, dense, and slow at...

Im Focus: Shrinking the proton again!

Scientists from the Max Planck Institute of Quantum Optics, using high precision laser spectroscopy of atomic hydrogen, confirm the surprisingly small value of the proton radius determined from muonic hydrogen.

It was one of the breakthroughs of the year 2010: Laser spectroscopy of muonic hydrogen resulted in a value for the proton charge radius that was significantly...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ASEAN Member States discuss the future role of renewable energy

17.10.2017 | Event News

World Health Summit 2017: International experts set the course for the future of Global Health

10.10.2017 | Event News

Climate Engineering Conference 2017 Opens in Berlin

10.10.2017 | Event News

 
Latest News

Electrode materials from the microwave oven

19.10.2017 | Materials Sciences

New material for digital memories of the future

19.10.2017 | Materials Sciences

Physics boosts artificial intelligence methods

19.10.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>